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Introduction 
Since the original paper by Peter Medawar in 1953, the question that has dominated the 
field of reproductive immunology is: “Why is the fetus not rejected?”  This question 
arose because Medawar (who had begun working on transplantation of skin grafts 
during WWII to treat pilots with burn injuries) showed that graft rejection is an 
immunological phenomenon (1,2).  His essay raised the question of why in pregnancy it 
is possible for two genetically different individuals to coexist without rejection of the 
fetus.  We describe here the immunological basis of allo-recognition and how this 
relates to human pregnancy. 
 
 Anatomy of Maternal/Fetal Interaction 
The implanting blastocyst is surrounded by trophectoderm that will develop into the 
definitive villous placenta as well as the invading extravillous trophoblast cells that 
invade into the uterus to tap into the maternal blood supply.  Villous trophoblast is in 
contact with maternal blood circulating through the intervillous space. Syncytial ‘knots’ 
are also shed from the villous placenta directly into the systemic circulation and become 
entrapped in the lung capillaries. EVT comes into direct contact with tissue immune 
cells in the decidua and myometrium of the uterus. Thus, fetal somatic cells are 
normally completely separated from the maternal immune system by the placental 
trophoblast barrier (3).   
 
Fetal cells can, however, cross over into the maternal circulation.  This usually occurs 
during the trauma at delivery (although they can also cross during spontaneous or 
therapeutic abortions) and these cells are capable of initiating immune responses.  In 
the early days of transplantation it was noted that multiparous women had antibodies 
to allogeneic leukocytes (allo-antibodies), now known to be specific for paternal Human 
leukocyte Antigens (HLA) (4).  The presence of these allo-antibodies has no influence on 
the outcome of pregnancy but will affect the mother’s chances of finding a compatible 
organ donor.  The presence of anti-D antibodies in women who are negative for this 
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blood group antigen also reveals that pregnant women can generate antibodies to fetal 
allo-antigens and they are therefore not immunosuppressed (5).  
 
 
Therefore, maternal immune responses in pregnancy should be considered separately 
as: 
 
• Systemic responses to fetal cells or soluble fetal antigens 
• Systemic responses to villous syncytiotrophoblast 
• Uterine immune responses to EVT. 
 
T cell allo-recognition 
The cells capable of allo-recognition are lymphocytes: T cells, Natural Killer (NK) cells, 
and B cells that produce antibodies with T cell help (6). 
 
T cells have a clonally-distributed receptor (TCR) that is generated during fetal 
development by somatic gene rearrangement.  Any T cells that have a TCR specific for a 
self HLA molecule presenting a self peptide are eliminated during T cell development to 
avoid self-reactivity (central tolerance).  Allo-reactive T cells will be present amongst 
the huge diversity of an individual’s T cells at a frequency of <10%.  These T cells will be 
able to respond and attack organ grafts unless there is HLA matching of donor and 
recipient.  
 
Rejection of solid organ grafts results from stimulation of the recipient’s immune 
system by two pathways: direct and indirect allo-recognition (6).  In direct allo-
recognition, donor dendritic cells, antigen presenting cells (APC) that express donor 
HLA molecules, migrate from the graft to the draining lymph node respectively. HLA 
class I and class II molecules bind directly to recipient’s CD8+ and CD4+ T cells in the 
lymph node. Effector T cells move into the graft with CD8+ T cells killing the graft and 
CD4+ T cells activating macrophages to initiate inflammation and providing help to B 
cells to produce antibodies. Indirect allo-recognition results from uptake of HLA and 
other allo-antigens from donor’s cells by recipient APC that drain to the regional lymph 
node.  Peptides derived from the donor’s HLA molecules are then presented to 
recipient’s T cells initiating a CD4+ allo-reaction. 
 
Why do maternal allo-reactive T cells not attack the fetal trophoblast?  Several 
mechanisms have been described in both humans and mice.  The villous 
syncytiotrophoblast never expresses any HLA class I or class II molecules so it is not 
possible for any T cells to bind to the main placental barrier, clearly a highly effective 
mechanism to protect the placenta from being killed (7).  The syncytial nature of the 
placental barrier is also likely to be important as small defects in the membrane can 
heal rapidly.  In contrast, the EVT does express HLA class I but never class II molecules 
so it cannot act as an APC initiating direct allo-recognition to CD4+ T cells.  
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Furthermore, the set of HLA class I molecules expressed is unusual: HLA-C, HLA-G and 
HLA-E.  Of these only HLA-C is polymorphic and so the paternal allele donated to the 
fetus will differ from the mothers.  HLA-G is monomorphic and is unique amongst HLA 
class I molecules as it forms a homodimer that can bind with high avidity to LILRB1, an 
inhibitory receptor expressed by all decidual APC.  This interaction probably deviates 
immune responses towards a tolerogenic rather than an immunogenic response (8).  
This has the added benefit of only occurring when there is direct physical contact 
between HLA-G+ EVT and uterine APC allowing maternal APC elsewhere in her body to 
function normally.   
 
Regulatory T cells (Tregs) can suppress allo-reactive CD4+ and CD8+ T cells and are 
generated in the decidua in pregnancy in both humans and mice probably because of 
the unique microenvironment rich in factors such as TGF (9).  However, it is still not 
clear whether the TCRs of these Tregs have any specificity for trophoblast HLA-C class I 
molecules although one study analysing T cells in the decidua at term has shown there 
are increased percentages of functional Tregs in HLA-C mismatched pregnancies (10). 
Other mechanisms described in murine models include reduced migration of APC to 
draining lymph nodes, failure of effector T cell accumulation in the decidua by silencing 
of stromal cell-derived chemokines and global effects of progesterone on immune cells 
(11). Mouse models may not be as helpful in studying reproductive failure as they have 
been for analysing the immunological basis of other human diseases.  Pregnancy in the 
mouse only last 19 days, there is no menstrual cycle, and the anatomy of placentation is 
different with little trophoblast invasion and formation of decidua only triggered by 
implantation and not in the secretory phase of the pre-pregnant endometrium. 
 
Although women in pregnancy are not immunosuppressed as seen by responses to 
paternal HLA and other allo-antigens, they do respond differently to infectious agents 
and auto-antigens.  For example, they are particularly susceptible to influenza, chicken 
pox and other viruses and the severity of auto-immune disorders such as rheumatoid 
arthritis and multiple sclerosis varies during pregnancy (12,13). This may be due to a 
deviation towards making better Th1 type responses (cytotoxic and effective for 
viruses) than antibody-generating Th2 type responses in pregnancy although robust 
evidence for this in humans is still lacking.  These alterations in the shape of immune 
responses in pregnant women are likely to result from enormous changes. Although 
these systemic changes in the type of immune responses seen in pregnancy mean, for 
example, that women need vaccination for influenza virus, it is important to state that 
there is still no evidence they have any impact on reproductive success and are likely to 
be an epiphenomenon secondary to the high levels of progesterone and other hormones 
and placental products. 
 
The important unanswered question is whether in humans T cells ever do bind and 
attack the trophoblast cells resulting in pregnancy failure?  Placental mammals evolved 
~150 million years ago and there must have been strong selective pressures to avoid T 
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cell rejection of the fetus. Because there are multiple mechanisms already described to 
avoid effector T cell responses that might damage trophoblast cells it seems unlikely 
that will ever all fail together.  Indeed, there are no convincing reports in humans that 
this does happen and that maternal T cells with specificity for trophoblast have caused 
killing of the placental cells.  Perhaps it is time to move away from Medawar’s famous 
question of 1953 and view the co-existence of the mother and her baby not as a 
dichotomy between rejection and acceptance but as a compromise. 
 
NK cells 
Although NK cells were only discovered in the 1970s, in evolutionary terms they are 
much older than T cells (14). Equivalent cytotoxic cells are present in invertebrates 
whereas T cells only appeared in teleost fishes.  NK cells resemble CD8+ T cells in many 
phenotypic, functional and morphological respects but crucially they lack a TCR 
generated by somatic gene rearrangement and rely on germ cell encoded receptors for 
target cell recognition.  NK cells are particularly important in the early stages of viral 
infection and cancer.  They were originally thought to be able to kill cells independently 
of HLA class I molecules but it then became clear that they are inhibited by binding to 
self-HLA and will therefore kill cells that lack self HLA class I molecules – known as the 
missing self response (15).  Thus, CD8+ T cells kill cells expressing non-self HLA whilst 
NK cells kill cells lacking self HLA class I molecules; either the detection of a difference 
(T cells) or the absence of a similarity (NK cells).  The findings that NK cells are the 
dominant lymphoid cells (~50-70% leukocytes) present at the time the placenta 
implants and become established led to the idea that they are the cells capable of allo-
recognition the fetal EVT (16).  T cells are present in early decidua but only account for 
~5-20% of leukocytes.  The remaining cells are CD14+ macrophages together with a 
few dendritic cells.  The observation that B cells and plasma cells are rare means it is 
highly unlikely that antibodies to EVT are locally generated. 
 
Uterine NK cells (uNK) are phenotypically distinct from those circulating in blood; they 
are CD56superbright, CD16- whereas 90% of blood NK cells are CD56dim, CD16+ (17).  The 
minor CD56bright population in blood also differ from those in the uterus 
morphologically and for many other surface markers.  These differences mean that 
measurements of any NK parameters in NK cells from blood will not be informative in 
relation to function of uNK (18).  Uterine NK cells proliferate and differentiate in the 
mucosa and may originate from a resident progenitor cell or from a progenitor cell 
recruited from the blood.  They are not present pre-menarche or post-menopausally 
and their dependence on the ovarian hormone, progesterone, is obvious from the great 
surge in proliferative activity after ovulation. This is mediated by increased expression 
of IL-15 from stromal cells in response to progesterone.  The presence of uNK in the 
decidua is maximal in the first trimester and numbers thereafter fall so although they 
are still present at term they are not abundant (19).  The functions of uNK are 
essentially unknown but available evidence suggests that they play a role in regulating 
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placentation and access of EVT to the spiral arteries that are the feto-placental supply 
line. 
 
NK allo-recognition 
NK cells are important clinically in haematopoietic transplantation.  HLA matching 
between donor and recipient prevent the problem of graft-versus-host-reaction (GVHR) 
when donor T cells attack recipient’s cells.  Haploidentical transplants are used when no 
HLA-matched donors can be found for the patient, as most will have a family member 
who will share one of their two HLA haplotypes (20).  The grafts need to be depleted of 
T cells to prevent GVHR and after engraftment donor NK cells will reconstitute rapidly 
in the recipient.  These donor NK cells can be highly effective in recognising allogeneic 
recipient cells and create a beneficial graft-versus-leukaemia (GVL) effect (21).   
 
Whether GVL occurs depends on receptors expressed by NK cells known as killer 
immunoglobulin-like receptors (KIR) that are germ-line encoded (22).  The KIR gene 
family is highly variable between individuals both in the number of KIR genes inherited 
and additionally with allelic variability at each KIR locus.  KIR genes can either impart 
an inhibitory or an activating signal to the NK cell and its overall functional response 
depends on the balance between the inhibitory and activating input to the cell following 
target recognition. The extent of KIR polymorphism is as great as for HLA genes and 
these two gene families are far more variable than any others in the human genome 
with large differences in frequency of variants in different populations. Some KIR 
expressed by NK cells bind to some groups of HLA-B (Bw4) and HLA-A (A3 and A11) 
class I molecules, but the dominant ligands for KIR are HLA-C molecules (22). The best 
scenario for effective GVL is if the recipient’s residual leukaemic cells lack an HLA-C 
ligand for an inhibitory KIR expressed by donor’s engrafting NK cells – missing self.  In 
this situation the donor NK cells are not inhibited by recipient HLA-C and will kill the 
leukaemic cells (23). 
 
Maternal NK recognition of fetus 
NK allo-recongition occurs in the placental bed in the uterus in a physiological not 
iatrogenic context.  The mother inherits a particular set of KIR genes, two KIR 
haplotypes, from her parents.  Broadly speaking these can be classified as KIR A or KIR 
B haplotypes.  KIR A haplotypes only have inhibitory KIR but KIR B haplotypes have 
varying numbers of additional mainly activating KIR.  Because the only HLA KIR ligand 
expressed by EVT are HLA-C molecules and these are the only polymorphic trophoblast 
HLA molecules, they provide a paternal HLA-C ligand for KIR expressed by maternal 
uNK.  All the alleles of HLA-C can be divided into 2 groups, C1+HLA-C and C2+HLA-C, 
depending on the sequence of the KIR-binding site of the HLA molecules (KIR epitope).  
The possible combinations of maternal NK KIR interactions with fetal EVT HLA-C 
groups are illustrated (Fig. 1).  Genetic studies show that the women who are most at 
risk of disorders of pregnancy associated with defective placentation (pre-eclampsia, 
unexplained stillbirth, fetal growth restriction) are more likely to have two KIR A 
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haplotypes with a fetal C2+HLA-C derived from the father (24,25).  How this translates 
into different functions of uterine NK cells compared to pregnancies with different 
maternal KIR/fetal HLA-C combinations is under intense investigation. There is a very 
strong inhibitory signal imparted to uNK cells following binding of inhibitory KIR to 
C2+HLA-C molecules.  
 
This type of allo-recognition based on NK cells is only operating in a normal 
physiological situation during early pregnancy when the placenta implants.  The 
hypothesis we are investigating is that NK allo-recognition system defines the territorial 
boundary between the two genetically different individuals during placentation.  This 
allows controlled invasion during placentation so the arteries are effectively 
transformed by trophoblast without undue penetration of the uterus. This border 
control is needed to balance the allocation of resources between mother and baby so 
that both can survive and flourish; thus, cooperative allo-recognition not leading to 
rejection or killing. 
 
 
 
Figure Legend 
Figure 1. Possible interactions between maternal KIR and fetal HLA-C molecules 
depend on KIR and HLA-C variants respectively present in the mother and fetus. 
Women can have inhibitory or activating KIR for which there is no HLA-C ligand in the 
fetus. The genetic combination of a mother with two KIR A haplotypes with a fetus 
carrying a group C2+HLA-C allele is associated with increased risk of pre-eclampsia. 
There is a very strong inhibitory signal from a fetal C2+HLA-C when maternal NK cells 
lack activating KIR (not present on KIR A haplotype). There is a protective effect for pre-
eclampsia when a mother has an activating KIR for C2+ HLA-C that is found on KIR B 
haplotypes. Adapted from (26). 
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